Letro-Cell (Letrozole)

Letro-Cell, an aromatase inhibitor, is used in the management of estrogen‑driven breast cancer.

• Hormone receptor‑positive breast cancer in postmenopausal women: reduces tumor progression by decreasing peripheral estrogen synthesis.
• Adjuvant therapy after surgery for early‑stage disease: lowers recurrence risk when combined with other oncologic treatments.
• Metastatic breast cancer in postmenopausal patients: provides disease control by limiting estrogen‑mediated tumor growth.

• Letrozole selectively and non‑steroidally inhibits the aromatase enzyme, which converts androstenedione and testosterone into estrone and estradiol. By blocking this conversion, systemic estrogen concentrations fall, depriving estrogen‑dependent tumor cells of a key growth stimulus and thereby inhibiting cancer proliferation.

Letro-Cell may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Hot flashes: transient feeling of warmth and sweating.
• Arthralgia: joint pain or stiffness.
• Nausea: mild to moderate upset stomach.
• Fatigue: reduced energy levels.
• Headache: mild to moderate intensity.
• Increased sweating: excessive perspiration.

Serious or Rare Side Effects

• Osteoporosis or bone fracture: decreased bone mineral density.
• Severe liver injury: elevated transaminases or hepatitis.
• Cardiovascular events: thromboembolism or myocardial infarction.
• Severe allergic reaction: rash, angioedema, or anaphylaxis.

Before initiating Letro-Cell, clinicians should evaluate several safety considerations.

• Monitor bone health: assess baseline density and consider calcium/vitamin D supplementation.
• Assess liver function: obtain hepatic enzyme tests prior to and during therapy.
• Contraindicated in pregnancy: letrozole is Category X and must not be used by pregnant individuals.
• Evaluate cardiovascular risk: review history of thromboembolic disease or myocardial infarction.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Letro-Cell can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Estrogen replacement therapy: may counteract letrozole’s estrogen‑lowering effect.
• Strong CYP2A6 inducers (e.g., rifampin): can markedly reduce letrozole plasma concentrations.
• Tamoxifen: antagonistic action may diminish therapeutic benefit.

Moderate Interactions (Monitor Closely)

• Anticoagulants such as warfarin: increased risk of bleeding; monitor INR.
• CYP2C19 inhibitors (e.g., fluconazole): may raise letrozole exposure, watch for toxicity.
• Diuretics: monitor electrolytes and renal function during combined use.